Crescendo Bioscience Announces Six Studies with Vectra® DA Will Be Presented at the 2017 Annual European Congress of Rheumat...
June 08 2017 - 7:05AM
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics,
Inc. (NASDAQ:MYGN), today announced that new data on the use of the
Vectra® DA test will be presented at the European League Against
Rheumatism (EULAR) meeting being held June 14-17, 2017, in
Madrid. Vectra DA is the only multi-biomarker blood test
proven to measure disease activity and predict joint damage
progression in patients with rheumatoid arthritis in a number of
clinical studies.
"We are excited to present several new studies, several of which
were done in collaboration with our academic partners, at this
year’s EULAR meeting. We continue to expand the body of
clinical data supporting Vectra DA and demonstrate the clinical
utility of the test," said Elena Hitraya, M.D., Ph.D., chief
medical officer, Crescendo Bioscience. “The rheumatology
community is taking great interest in biomarkers and their ability
to help personalize treatment plans and achieve better health
outcomes for their patients with RA."
A list of the Vectra DA presentations at EULAR 2017 is
below. Follow Vectra DA on Twitter via @VectraDA and Myriad
via @MyriadGenetics to stay informed about symposium news and
updates by using the hashtag #EULAR2017.
Title |
|
Author |
|
Poster Number |
|
Day/Time |
|
PosterSession |
|
|
|
|
|
|
|
|
|
Vectra DA Podium
Presentation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Multi-Biomarker Disease
Activity and Autoantibody Status Lead To Cost Effective Tapering
Algorithms in Rheumatoid Arthritis Patients in Sustained
Remission |
|
M. Hagen |
|
OPO249 |
|
Friday, June 16,
2017:10:15 a.m. – 11:45 a.m.CEST. |
|
RA – Causes and
Courses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vectra DA Poster
Presentations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Daily and Diurnal
Variation and Determination of the Minimally Important Difference
in Rheumatoid Arthritis Patients with Moderate to High
Multi-Biomarker Disease Activity Scores (MID) |
|
David Chernoff |
|
THU0087 |
|
Thursday, June 15, 2017:
11:45 a.m. - 1:30 p.m. CEST. |
|
Session I |
|
|
|
|
|
|
|
|
|
High multi-biomarker
disease activity score is associated with high risk of radiographic
progression in six studies (Meta-Analysis) |
|
Eric Sasso |
|
THU0091 |
|
Thursday, June 15, 2017:
11:45 a.m. - 1:30 p.m. CEST. |
|
Session I |
|
|
|
|
|
|
|
|
|
Determining Minimum
Clinically Important Change in Multi Biomarker Disease Activity
Score Associated with Clinical Improvement in Methotrexate Naïve
Patients with Early Rheumatoid Arthritis (EIRA) |
|
Katerina
Chatzidionysiou |
|
FRI0100 |
|
Friday, June 16, 2017:
11:45 a.m. - 1:30 p.m. CEST. |
|
Session II |
|
|
|
|
|
|
|
|
|
Multi-biomarker disease
activity (MBDA) is associated with the progression of structural
bone damage in rheumatoid arthritis patients in remission |
|
G. Schett |
|
THU0096 |
|
Thursday, June 15, 2017:
11:45 a.m. - 1:30 p.m. CEST. |
|
Session I |
|
|
|
|
|
|
|
|
|
Elevated multi-biomarker
disease activity (MBDA) predicts relapse in RA patients in
sustained remission tapering tumour necrosis factor inhibitor
therapy- Results from the randomized controlled RETRO study |
|
J. Rech |
|
FRI0098 |
|
Friday, June 16,
2017:11:45 a.m. – 1:30 p.m.CEST. |
|
Session II |
|
|
|
|
|
|
|
|
|
The efficacy of Vectra DA has been proven in more than 35
studies with more than 3,000 patients. The clinical utility for
Vectra DA has been widely recognized as three out of four
rheumatologists have used Vectra DA and have ordered it for more
than 300,000 patients in the United States. Recently, Vectra
DA was included in guidelines published by United Rheumatology and
will be evaluated for inclusion in the American College of
Rheumatology (ACR) guidelines. Additionally, Creaky Joints, a
leading advocacy group for patients with RA added Vectra DA to its
professional guidelines, which underscores the importance of Vectra
DA to the patient community.
For more information about these presentations,
including a complete list of abstracts and presentations, please
visit the EULAR website at http://www.congress.eular.org/.
About Vectra® DA Vectra DA is the only
multi-biomarker blood test for rheumatoid arthritis disease
activity that integrates the concentrations of 12 serum proteins
associated with RA disease activity into a single objective score,
on a scale of 1 to 100, to help physicians make more informed
treatment decisions. Vectra DA testing is performed at the
Crescendo Bioscience state-of-the-art CLIA (Clinical Laboratory
Improvement Amendments) facility. Test results are reported to the
physician 5 to 7 days from shipping of the specimen to Crescendo
Bioscience. Physicians can receive test results via standard mail,
by fax or via the private web portal, VectraView. For more
information on Vectra DA, please visit: www.Vectra-DA.com.
About Crescendo BioscienceCrescendo Bioscience,
a wholly-owned subsidiary of Myriad Genetics, Inc., is a molecular
diagnostics company dedicated to developing and commercializing
quantitative blood tests for rheumatoid arthritis (RA) and other
autoimmune diseases, located in South San Francisco, Calif.
Crescendo Bioscience develops quantitative, objective, reproducible
blood tests to provide rheumatologists with deeper clinical insight
to help enable more effective management of patients with
autoimmune and inflammatory diseases. For more information,
please visit the company website at www.CrescendoBio.com.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
three strategic imperatives: transitioning and expanding its
hereditary cancer testing markets, diversifying its product
portfolio through the introduction of new products and increasing
the revenue contribution from international markets. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, Vectra, Prolaris EndoPredict and GeneSight are
trademarks or registered trademarks of Myriad Genetics, Inc. or its
wholly owned subsidiaries in the United States and foreign
countries. MYGN-F,
MYGN-G
Safe Harbor StatementThis press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
relating to the Vectra DA data to be presented at the 2017 Annual
European Congress of Rheumatology (EULAR) Annual Meeting, June
14-17, 2017 in Madrid.; the potential clinical utility of the
Vectra DA study results and findings for guiding treatment
decisions in patients with RA; and the Company's strategic
directives under the captions "About Crescendo Bioscience" and
"About Myriad Genetics." These "forward-looking statements" are
based on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk that sales
and profit margins of our molecular diagnostic tests and
pharmaceutical and clinical services may decline; risks related to
our ability to transition from our existing product portfolio to
our new tests, including unexpected costs and delays; risks related
to decisions or changes in governmental or private insurers’
reimbursement levels for our tests or our ability to obtain
reimbursement for our new tests at comparable levels to our
existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services and any future tests and services are terminated or cannot
be maintained on satisfactory terms; risks related to delays or
other problems with operating our laboratory testing facilities and
our healthcare clinic; risks related to public concern over genetic
testing in general or our tests in particular; risks related to
regulatory requirements or enforcement in the United States and
foreign countries and changes in the structure of the healthcare
system or healthcare payment systems; risks related to our ability
to obtain new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire; risks related to our projections about our business,
results of operations and financial condition; risks related to the
potential market opportunity for our products and services; the
risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents or other intellectual property; risks
related to changes in intellectual property laws covering our
molecular diagnostic tests and pharmaceutical and clinical services
and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et
al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of our most recent Annual Report on Form 10-K for the
fiscal year ended June 30, 2016, which has been filed with the
Securities and Exchange Commission, as well as any updates to those
risk factors filed from time to time in our Quarterly Reports on
Form 10-Q or Current Reports on Form 8-K. All information in
this press release is as of the date of the release, and Myriad
undertakes no duty to update this information unless required by
law.
Media Contact:
Ron Rogers
(908) 285-0248
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024